Free tool
FAERS Monitor: Menopur
Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 021663 or its brand name (Menopur, Menotropins (Fsh, Lh)). Reports on generic versions are filed under their own applications.
Reports
2,221
Serious
1,027
46% of reports
Hospitalization
598
Death reported
32
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- ovarian hyperstimulation syndrome434
- abdominal distension198
- drug ineffective178
- injection site pain151
- headache141
- nausea133
- abdominal pain115
- ascites95
- dyspnoea84
- inappropriate schedule of drug administration81
- fatigue73
- abortion spontaneous69
- vomiting61
- maternal exposure during pregnancy54
- dizziness51
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 11 |
| 2005 | 19 |
| 2006 | 21 |
| 2007 | 45 |
| 2008 | 37 |
| 2009 | 21 |
| 2010 | 30 |
| 2011 | 36 |
| 2012 | 38 |
| 2013 | 63 |
| 2014 | 82 |
| 2015 | 80 |
| 2016 | 88 |
| 2017 | 149 |
| 2018 | 114 |
| 2019 | 263 |
| 2020 | 148 |
| 2021 | 197 |
| 2022 | 166 |
| 2023 | 169 |
| 2024 | 135 |
| 2025 | 127 |
| 2026 | 182 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,938 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| ovarian hyperstimulation syndromeSignal | 434 | 2166.2 | 1968.7 | 762,875 |
| ascitesSignal | 95 | 30.7 | 25.2 | 2,695 |
| abdominal distensionSignal | 198 | 18.0 | 15.8 | 3,171 |
| abortion spontaneousSignal | 69 | 16.3 | 12.9 | 978 |
| inappropriate schedule of drug administrationSignal | 81 | 10.8 | 8.7 | 712 |
| maternal exposure during pregnancySignal | 54 | 5.7 | 4.4 | 207 |
| abdominal painSignal | 115 | 4.7 | 3.9 | 333 |
| injection site painSignal | 151 | 4.7 | 4.0 | 437 |
| headacheSignal | 141 | 2.1 | 1.8 | 86 |
| nausea | 133 | 1.6 | 1.3 | 30 |
| dyspnoea | 84 | 1.4 | 1.1 | 10 |
| drug ineffective | 178 | 1.3 | 1.1 | 11 |
| vomiting | 61 | 1.2 | 1.0 | 2 |
| dizziness | 51 | 1.0 | 0.7 | 0 |
| fatigue | 73 | 0.9 | 0.7 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.